嵌合抗原受体T细胞治疗后症状负担患者报告结局测量工具的开发和验证
本横断面研究开发并验证了用于评估嵌合抗原受体(CAR)T细胞治疗后症状负担和日常功能的患者报告结局工具MDASI-CAR。最终10个条目模块内部一致性高(Cronbach's alpha:MDASI核心0.865,干扰0.915,CAR-T模块0.746),已知组效度良好(基于体能状态的Cohen's d:核心-1.008,干扰-0.771,模块-0.835),效标效度显示与生活质量单条目及PROMIS-29相关域显著相关(均p<0.05)。研究认为MDASI-CAR是可靠有效的工具,但需纵向设计验证。
要点
- MDASI-CAR模块含10个条目:震颤、发热/寒战、头痛、平衡、头晕、注意力、言语困难、咳嗽、性功能障碍、腹泻。
- 内部一致性Cronbach's alpha:MDASI核心0.865,干扰0.915,CAR-T模块0.746。
- 基于体能状态区分患者的已知组效度Cohen's d:核心-1.008,干扰-0.771,模块-0.835。
核心结论
- 本研究确立MDASI-CAR模块为可靠且有效的患者报告结局工具,用于监测血液恶性肿瘤患者CAR T细胞治疗后的症状负担。
- 研究结果需通过纵向设计进行验证。
研究设计与样本
- 横断面研究,开发并验证CAR T细胞治疗后症状负担和日常功能的患者报告结局评估工具MDASI-CAR。
- 条目基于文献回顾、患者内容启发访谈和临床医生审查生成。
- 患者完成MDASI核心和模块、单条目生活质量测量和PROMIS-29。
主要发现
- 最终10个MDASI-CAR模块条目包括震颤、发热/寒战、头痛、平衡、头晕、注意力、言语困难、咳嗽、性功能障碍和腹泻。
- 内部一致性Cronbach's alpha:MDASI核心0.865,MDASI干扰0.915,CAR-T模块0.746。
- 已知组效度通过基于体能状态区分患者证明,Cohen's d:MDASI核心-1.008,干扰-0.771,模块-0.835。
- 效标效度通过MDASI-CAR综合评分与单条目生活质量及PROMIS-29相关域之间的显著相关性证明(所有p<0.05)。
局限性
- 研究结果需通过纵向设计进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This cross-sectional study aimed to develop and validate a patient-reported outcomes (PROs) assessment tool to assess symptom burden and daily functioning in patients after chimeric antigen receptor (CAR) T-cell therapy, the MD Anderson Symptom Inventory (MDASI-CAR). The items were generated based on literature review, content elicitation interviews with patients, and clinician's review. The patients completed the MDASI core and module, single-item quality-of-life (QoL) measure and Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29). The psychometric validation analysis was based on the acceptability after item reduction process. The final 10 MDASI-CAR module items included tremors, fever/chills, headache, balance, dizziness, attention, difficulty speaking, coughing, sexual dysfunction, and diarrhoea with high internal consistency (Cronbach's alpha: MDASI Core, 0.865; MDASI Interference, 0.915; CAR-T module, 0.746). The MDASI-CAR has excellent known-group validity that was demonstrated by differentiate patients based on patient's performance status (Cohen's d for MDASI core = -1.008, interference = -0.771, module = -0.835). Criterion validity was demonstrated by the significant correlations between the MDASI-CAR composite score, the single QoL item and the relevant domains on PROMIS-29 (all p < 0.05). This study established the MDASI-CAR module as a reliable and valid PRO tool for monitoring symptom burden after CAR T-cell therapy in patients with haematological malignancies. The findings need to be validated with a longitudinal design.
引用
- Wang XS, Srour SA, Mendoza T, et al. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol. 2023. PMID: 36733986. doi:10.1111/bjh.18677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。